Recombinant Clostridium difficile Antigen Design
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for Clostridium difficile infection (CDI) are inadequate due to the inefficacy of antibiotics, particularly against more virulent strains, and the challenges in producing and purifying natural toxins, leading to a need for new vaccine and therapeutic options that can effectively neutralize Toxin A and Toxin B.
Innovation Solution
Development of protective polypeptide antigens comprising amino acid sequences with at least 90% identity to C. difficile Toxin B, excluding Repeat Units, and methods for generating antibodies that bind and neutralize Toxin B, including recombinant antigen production and affinity purification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If natural toxins are used as antigens for immunisation, then the immune response is potent and protective, but the manufacturing process is difficult and costly due to purification challenges
Solution Approach 1:
The patent creates recombinant polypeptide copies of the toxin B antigen that mimic the immunogenic properties of natural toxins without requiring purification from complex toxin mixtures. The recombinant antigen is produced through genetic engineering in expression systems, providing a simplified manufacturing pathway while maintaining protective immune response capability
Solution Approach 2:
The invention extracts only the essential immunogenic portion of toxin B (amino acid sequence without repeat units) and produces it as a standalone recombinant polypeptide. This extraction of the critical antigenic domain eliminates the need to purify entire toxin molecules, simplifying manufacturing while preserving protective immunity
2Stability of the object's composition
If repeat units are included in the antigen polypeptide, then the structural完整性 is maintained, but the immunogenicity and neutralizing capability are reduced
Solution Approach 1:
The patent removes the repeat unit regions from the toxin B sequence, retaining only the essential immunogenic domains (amino acid residues that elicit protective antibodies). This extraction demonstrates that the repeat units are not necessary for inducing protective immune responses, and their removal simplifies the antigen structure while maintaining or enhancing immunogenicity
Solution Approach 2:
The invention applies local quality by concentrating the antigenic epitopes in specific regions of the polypeptide that are known to be immunogenic, while excluding non-essential repeat regions. This localized approach to antigen design optimizes the immune response by focusing on the most effective protective domains
3Ease of operation
If antibiotics are used to treat CDI, then the treatment is simple and widely available, but the efficacy is insufficient particularly against virulent strains with high relapse rates
Solution Approach 1:
The patent introduces antibodies as an intermediary mechanism to neutralize toxin B activity. Rather than relying solely on antibiotics to kill bacteria, the recombinant antigen induces antibody production that directly neutralizes the pathogenic toxins, providing an additional layer of protection that addresses treatment failure and relapse
Solution Approach 2:
The invention employs preliminary anti-action through active immunization, where the recombinant antigen is administered beforehand to induce protective antibodies before toxin exposure occurs. This preventive approach equips the immune system with neutralizing antibodies that can immediately counteract toxin B, preventing disease progression and reducing relapse risk
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polypeptide antigens induce a potent toxin-neutralizing immune response, providing prophylactic and therapeutic benefits against CDI, with improved manufacturing feasibility and efficacy compared to previous approaches.
Implementation Method 1
The polypeptide antigens induce a potent toxin-neutralizing immune response
Implementation Method 2
Development of protective polypeptide antigens comprising amino acid sequences with at least 90% identity to C. difficile Toxin B
Implementation Method 3
methods for generating antibodies that bind and neutralize Toxin B, including recombinant antigen production and affinity purification
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to recombinant Clostridium difficile antigens based on a polypeptide, consisting of or comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence consisting of residues 1500-700 of a C. difficile Toxin A sequence or a C. difficile Toxin B sequence; though with the proviso that the polypeptide does not include one or more Repeat Unit (RU) located between amino acid residues 1851-2710 of C. difficile Toxin A and/ or residues 1853-2366 of a C. difficile Toxin B protein that consists of or comprises a first amino acid sequence and a second amino acid. Also provided is the use of said antigens for the prevention/ treatment/ suppression of Clostridium difficile infection (CDI), together with methods for generating said antigens, methods for generating antibodies that bind to said antigens, and the use of said antibodies for the prevention/ treatment/ suppression of CDI.